FERRERO, Simone
 Distribuzione geografica
Continente #
NA - Nord America 1.975
EU - Europa 1.338
AS - Asia 472
AF - Africa 34
OC - Oceania 25
SA - Sud America 25
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.870
Nazione #
US - Stati Uniti d'America 1.936
IT - Italia 523
DE - Germania 220
CN - Cina 134
NL - Olanda 114
IN - India 100
RU - Federazione Russa 86
CZ - Repubblica Ceca 80
VN - Vietnam 78
GB - Regno Unito 60
JP - Giappone 49
FR - Francia 47
ES - Italia 43
CA - Canada 30
ZA - Sudafrica 28
AT - Austria 26
PL - Polonia 23
AU - Australia 19
KR - Corea 19
CH - Svizzera 18
IE - Irlanda 15
DK - Danimarca 14
HK - Hong Kong 14
GR - Grecia 12
SG - Singapore 11
CL - Cile 10
RO - Romania 10
MX - Messico 9
TH - Thailandia 9
TR - Turchia 9
BR - Brasile 8
ID - Indonesia 8
TW - Taiwan 8
IL - Israele 7
SE - Svezia 7
IR - Iran 6
NZ - Nuova Zelanda 6
PK - Pakistan 6
UA - Ucraina 6
HU - Ungheria 5
MY - Malesia 5
BG - Bulgaria 4
FI - Finlandia 4
LT - Lituania 4
PT - Portogallo 4
BE - Belgio 3
KW - Kuwait 3
MK - Macedonia 3
CO - Colombia 2
EG - Egitto 2
MA - Marocco 2
PE - Perù 2
PH - Filippine 2
RS - Serbia 2
SA - Arabia Saudita 2
SC - Seychelles 2
AD - Andorra 1
AR - Argentina 1
BO - Bolivia 1
EC - Ecuador 1
EU - Europa 1
IQ - Iraq 1
IS - Islanda 1
KZ - Kazakistan 1
NO - Norvegia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.870
Città #
Fairfield 209
Ashburn 150
Torino 148
Santa Cruz 134
Houston 126
Woodbridge 123
Buffalo 97
Seattle 90
Cambridge 77
Ann Arbor 68
Wilmington 67
Dong Ket 60
Beijing 47
Turin 34
Milan 28
Chicago 24
Fleming Island 24
Vienna 24
Nürnberg 23
Muizenberg 22
Pisa 20
Almere 19
Rome 19
San Diego 18
Warsaw 18
Mountain View 17
Bengaluru 16
Rochester 16
University Park 15
Wuhan 15
Nuenen 14
Dublin 13
Las Vegas 13
New York 13
Chennai 12
Riva 12
Clearwater 11
Los Angeles 11
Alkmaar 10
Lake Forest 10
Provo 10
Shanghai 10
Odense 9
Portland 9
Ciriè 8
Collegeville 8
Rotterdam 8
Barcelona 7
Boardman 7
Council Bluffs 7
Des Moines 7
Duncan 7
Leawood 7
Madrid 7
Ottawa 7
Sydney 7
Taipei 7
Tokyo 7
Varallo Pombia 7
Ankara 6
Brooklyn 6
Chongqing 6
Delhi 6
Florence 6
Heidelberg 6
Milpitas 6
Oberboihingen 6
San Francisco 6
San Jose 6
Yokohama 6
Christchurch 5
Dallas 5
Frankfurt am Main 5
Hartford 5
Henderson 5
Madison 5
Mumbai 5
Osaka 5
Palermo 5
Philadelphia 5
Phoenix 5
San Mateo 5
Stockholm 5
Tianjin 5
Andratx 4
Baltimore 4
Chengdu 4
Durham 4
Guangzhou 4
London 4
New Kensington 4
Norwalk 4
Paris 4
Pavia 4
Saint Petersburg 4
Southampton 4
Tappahannock 4
Toronto 4
Tsukuba 4
Valdagno 4
Totale 2.213
Nome #
ABVD vs BEACOPP escalated in advanced-stage Hodgkin’s lymphoma: Results from a multicenter European study, file e27ce432-1790-2581-e053-d805fe0acbaa 441
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma, file e27ce427-77e8-2581-e053-d805fe0acbaa 344
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial, file e27ce42c-4faf-2581-e053-d805fe0acbaa 300
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma, file e27ce426-ff25-2581-e053-d805fe0acbaa 179
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease, file e27ce42f-816b-2581-e053-d805fe0acbaa 178
New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies, file e27ce42f-4938-2581-e053-d805fe0acbaa 173
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma, file e27ce427-4b8d-2581-e053-d805fe0acbaa 166
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data, file e27ce42c-09a5-2581-e053-d805fe0acbaa 164
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia, file e27ce42c-516f-2581-e053-d805fe0acbaa 158
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study, file e27ce42f-37f8-2581-e053-d805fe0acbaa 136
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study, file e27ce430-3a9e-2581-e053-d805fe0acbaa 117
Droplet Digital PCR Assay for MYD88L265P, file e27ce42f-575c-2581-e053-d805fe0acbaa 116
Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma, file e27ce42f-3cd9-2581-e053-d805fe0acbaa 108
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes., file e27ce42e-c96b-2581-e053-d805fe0acbaa 105
Psychological distress and oral chemotherapy: a pilot study., file e27ce428-dbf5-2581-e053-d805fe0acbaa 103
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi, file e27ce431-f034-2581-e053-d805fe0acbaa 100
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue, file e27ce42f-3cd0-2581-e053-d805fe0acbaa 97
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis, file e27ce42f-6e99-2581-e053-d805fe0acbaa 94
Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?, file e27ce42e-b8bf-2581-e053-d805fe0acbaa 92
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL), file e27ce42f-9671-2581-e053-d805fe0acbaa 88
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma, file e27ce427-0a2c-2581-e053-d805fe0acbaa 76
Real life use of bendamustine in elderly patients with lymphoid neoplasia, file e27ce432-2046-2581-e053-d805fe0acbaa 73
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines, file e27ce42f-8163-2581-e053-d805fe0acbaa 65
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network, file e27ce42f-9670-2581-e053-d805fe0acbaa 57
Novel CALR somatic mutations in essential thrombocythaemia, file e27ce42b-fa13-2581-e053-d805fe0acbaa 51
Oral chemotherapy: an innovative choice, file e27ce42a-54df-2581-e053-d805fe0acbaa 47
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino, file e27ce42e-70fd-2581-e053-d805fe0acbaa 39
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR, file e27ce432-6173-2581-e053-d805fe0acbaa 36
Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment, file e27ce42f-8e57-2581-e053-d805fe0acbaa 34
The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial, file e27ce42e-6cf1-2581-e053-d805fe0acbaa 33
Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial, file 8147eea1-ed6e-4c9e-b8de-b8d70eeee4cc 31
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi, file e27ce42e-e4a5-2581-e053-d805fe0acbaa 28
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders, file e27ce42f-575a-2581-e053-d805fe0acbaa 26
COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL, file e27ce42e-6cf2-2581-e053-d805fe0acbaa 23
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma, file 4702f1ba-560f-4631-8476-c0543e70f82c 21
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia, file e27ce435-9268-2581-e053-d805fe0acbaa 20
Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study, file 8bfe5234-68f7-43e3-b818-e65c5fcad05a 17
COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL, file e27ce42e-6cf3-2581-e053-d805fe0acbaa 14
HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience, file ddc47db0-3197-4479-9923-bf2f533cc0e7 13
Novel CALR somatic mutations in essential thrombocythaemia, file e27ce427-642b-2581-e053-d805fe0acbaa 13
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia, file 57a5cb9c-fb45-4dbb-aaad-c6b34ead6bb5 8
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up, file e27ce42c-a111-2581-e053-d805fe0acbaa 7
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study, file e27ce42c-5f8d-2581-e053-d805fe0acbaa 6
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation, file e27ce430-1511-2581-e053-d805fe0acbaa 6
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program, file e27ce42f-3cde-2581-e053-d805fe0acbaa 4
COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment, file df5c8818-1251-4a20-92d7-9275b15268b0 3
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis, file e27ce42c-9139-2581-e053-d805fe0acbaa 3
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study, file e27ce42f-65b6-2581-e053-d805fe0acbaa 3
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi, file e27ce432-5f9f-2581-e053-d805fe0acbaa 3
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma, file e27ce426-d3d4-2581-e053-d805fe0acbaa 2
A 6-GENE EXPRESSION SIGNATURE IN MANTLE CELL LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)-MCL-0208 TRIAL, file e27ce42c-8c09-2581-e053-d805fe0acbaa 2
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death, file e27ce42f-8166-2581-e053-d805fe0acbaa 2
Maternal and Perinatal Outcomes of Pregnant Women with SARS-COV-2 infection, file e27ce431-ecbf-2581-e053-d805fe0acbaa 2
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes, file 6156d57e-440b-4f06-b6da-a02a8bae0e0a 1
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia, file e27ce426-b2e6-2581-e053-d805fe0acbaa 1
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells, file e27ce426-de74-2581-e053-d805fe0acbaa 1
Totale 4.030
Categoria #
all - tutte 5.478
article - articoli 0
book - libri 0
conference - conferenze 976
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.454


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019189 0 0 0 9 10 11 19 31 9 29 42 29
2019/2020563 24 11 17 44 25 26 28 61 64 68 87 108
2020/2021910 117 89 69 48 55 58 74 68 63 66 76 127
2021/20221.063 85 55 57 115 85 96 122 67 57 74 174 76
2022/2023944 37 52 158 115 80 63 85 91 109 83 59 12
2023/202474 14 27 33 0 0 0 0 0 0 0 0 0
Totale 4.030